Business
Hemostemix Contracts ProConsul to Ramp up Engagement with New Investors
Calgary, Alberta--(Newsfile Corp. - February 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTX...
About this update from Hemostemix Inc
[{"type":"text","content":"Hemostemix Contracts ProConsul to Ramp up Engagement with New Investors Calgary, Alberta--(Newsfile Corp. - February 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (\"Hemostemix\" or the \"Company\") is excited to announce that it has engaged ProConsul Capital Ltd. (\"ProConsul\"), to provide investment marketing consulting services (the \"Services\") commencing February 6th, 2025. In consideration for the Services, the Company will pay a fee of $6,000/month and has agreed to grant stock options to ProConsul. The number and terms of the stock options will be determined at a later date, and announced by the Company. The agreement is renewable on a month-to-month basis unless terminated by either party on 30 days written notice.About HemostemixFounded in 2003, Hemostemix is a clinical-stage biotechnology company recognized for its patented blood-based stem cell therapeutics platform. Hemostemix is focused on scaling angiogenic, neuronal, and cardiomyocyte cell precursors, to treat no-option patients worldwide.Learn more: www.hemostemix.comContact: Thomas Smeenk, President & CEO - [email protected] | (905) 580-4170Stock Information: (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0)Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Forward-Looking Information: This news release contains \"forward-looking information\" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to sales of its lead product ACP-01, the commercialization of ACP-01 via the sale of compassionate treatments under Special Access Program. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying ...